(English) Fortress Biotech, Inc.
Join Class Action »
(English) SHAREHOLDER ALERT: Zhang Investor Law Announces a Securities Class Action Lawsuit Against Fortress Biotech, Inc. – FBIO
New York, N.Y., December 2, 2020. Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Fortress Biotech, Inc. (NASDAQ: FBIO) between December 11, 2019 and October 9, 2020, inclusive (the “Class Period”).
To join the FBIO class action, go to http://zhanginvestorlaw.com/cases/fortress-biotech-inc/ call Sophie Zhang, Esq. toll-free at 800-991-3756 or email email@example.com for information on the class action.
Lead plaintiff status is not required to seek compensation. You may retain counsel of your choice. You may remain an absent class member and take no action at this time.
According to the lawsuit, throughout the Class Period (1) IV Tramadol was not safe for the intended patient population; (2) as a result, it was foreseeable that the FDA would not approve the NDA for IV Tramadol; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 26, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://zhanginvestorlaw.com/cases/fortress-biotech-inc/ or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. of Zhang Investor Law toll free at 800-991-3756 or via e-mail at firstname.lastname@example.org.
Zhang Investor Law represents investors worldwide.